3European public assessment report (EPAR) rasilez summary for the public[EB/OL].2009-04.http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm.
4MHRA Drug Safety Update.Aliskiren (Rasilez):risk of angioedema and renal dysfunction[EB/OL].2009,2(10):2-3.http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON046451.
5EMEA.European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines[EB/OL].2009-2-19.http://www.emea.europa.eu/pdfs/human/press/pr/8952309en.pdf.
二级参考文献14
1FEIDMAN D L, ZELENKOFSKE S, DINBOECK M, et al. Use of renin inhibitors, alone or in combination with other agents, for treatment of cardiovascular and other diseases: WO, 2005/089731 [P]. 2005 - 09 - 29.
2WEBB R L. Drug combination for treatment of cardiovascular disorders: WO, 2007/056324 [P]. 2007 - 05 - 18.
3WEBB R L. Combination chemotherapy containing renin inhibitors and antiobesity agents for the treatment of dyslipidemia and obesity.. WO, 2007/048027 [ P]. 2007 - 04 - 26.
4LINDSAY K B, SKRYDSTRUP T. Formal total synthesis of the potent renin inhibitor aliskiren: application of a smi2-prorooted acyl-like radical coupling[J]. J Org Chem, 2006, 71 (13) : 4766 - 4777.
5DONG H, ZHANG Z L, HUANG J H, et al. Practical synthesis of an orally active renin inhibitor aliskiren [J]. Tetrahedron Lett, 2005, 46(37) :6337 - 6340.
6AZIZI M, MENARD J, BISSERY A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the ATI receptor antagonist valsartan on the angiotensin II-renin feedback interruption [ J]. Am Soc Nephrol , 2004,15(12) :3126-3133.
7AZIZI M, WEBB R, NUSSBERGER J, et al. Renin inhibition with aliskiren : where are we now, and where are we going? [ J ]. Hypertens, 2006,24 ( 2 ) : 243-256.
8WALDMEIER FJ,GLAENZEL U, WIRZ B ,et al. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers [ J/OL] .2007, as doi: 10. 1124/dmd. 106. 013797.
10GRADMAN A H, SCHMIEDER R E, LINS R L, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients [ J ]. Circulation, 2005, 111 : 1012-1018.
